Disgren (Triflusal) is commonly used in high-risk patient populations to address the potential for recurrent vascular events. Its use is focused on minimizing the potential for serious, recurrent vascular events and their associated symptomatic burden.

Disgren is primarily relevant for supporting the secondary management of cerebrovascular events, such as ischemic stroke and transient ischemic attack (TIA). It is also commonly used in the chronic management of acute coronary syndromes and is relevant for easing symptoms associated with peripheral arteriopathy, like functional limitations in walking. The medication assists with ongoing support following events, which helps in managing the potential for future recurrence. This application is also considered relevant for prophylactic use following specific procedures, such as aortocoronary vein bypass grafting, to support the maintenance of the new grafts.

Quick Fact: Support for Vascular Risk Management The medication can support general well-being during the long-term management of high-risk vascular conditions.

Disgren (triflusal) is an antiplatelet agent used primarily for the secondary prevention of cardiovascular events. This means it is typically prescribed to adults who have already experienced a thrombotic event, such as a myocardial infarction (heart attack) or certain types of stroke (non-hemorrhagic cerebrovascular accident). It is also indicated for patients who have undergone coronary bypass surgery to reduce the risk of graft occlusion.

Contraindications

Disgren is not suitable for all patients. It is strictly contraindicated if you have:

• Active bleeding or any disorder that causes hemorrhage (uncontrolled bleeding).
• An active peptic ulcer (stomach or duodenal ulcer) or a history of complicated peptic ulcers.
• Hypersensitivity (severe allergy) to triflusal, any other ingredient in the medication, or other salicylates (a group of drugs that includes aspirin).

Special Precautions

Close medical supervision is necessary, and the drug must be used with caution, in the following situations:

Condition	Precaution
Pregnancy/Lactation	Use is not established and should be carefully weighed by a doctor.
Kidney or Liver Impairment	Limited experience; caution is required.
Scheduled Surgery	Treatment may need to be discontinued several days before the procedure due to the increased risk of bleeding.

Disgren is not recommended for use in children or adolescents under 18 years of age, as safety and efficacy have not been established in this population.

Interactions with other medicines and products

The interaction profile of Disgren (Triflusal) is primarily defined by pharmacodynamic interactions that influence the risk of bleeding. Regulatory agencies emphasize that caution is required when co-administering this medicine with specific drug classes that also affect coagulation or platelet function.

---

Documented Interaction Patterns

Category	Documented Interaction Entities / Outcome
Pharmacodynamic Interactions	Acetylsalicylic Acid (AAS) and other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Use requires special caution due to the documented potential for hemorrhagic risk.
Interacting Product Classes	Antiplatelet agents, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
Administration Timing	Recommended to be taken preferably with meals.

---

Population-Specific Interaction Notes

Official prescribing information notes that interactions with other medicines require special care when administered to patients with renal or hepatic insufficiency. This caution is due to limited clinical experience in these populations when managing co-administration. No clinically relevant pharmacokinetic interactions involving specific enzyme or transporter pathways are formally specified in regulatory documents. The most significant constraint is tied to the amplification of the antiplatelet effect when combined with other agents that affect coagulation.

Disgren (Triflusal) functions as an antiplatelet agent through a multi-pathway pharmacodynamic mechanism mediated by its active metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid (HTB).

Irreversible Inhibition of TXA2 Synthesis

The metabolite HTB acts as an irreversible inhibitor of the Cyclooxygenase-1 (COX-1) enzyme specifically within platelets. This molecular modification halts the enzymatic conversion of arachidonic acid to Prostaglandin H2 ( PGH2), thereby blocking the synthesis of Thromboxane A2 ( TXA2), an effective promoter of platelet aggregation. The resultant decrease in TXA2 production reduces the blood’s capacity for thrombus formation.

Modulation of Vascular Tone and Anti-Adhesion

The mechanism extends to the vascular endothelium, where it includes activating inducible Nitric Oxide Synthase (iNOS) and inhibiting NF-kappa B activation. These actions increase the local bioavailability of Nitric Oxide (NO) while reducing the expression of adhesion molecules, contributing to vascular smooth muscle relaxation and reduced platelet adhesion to the vascular endothelium.

Interference with Intracellular Signaling

Additionally, the mechanism involves Phosphodiesterase (PDE) inhibition, which increases the intracellular concentration of the second messengers cyclic AMP (cAMP) and cyclic GMP (cGMP). This augmentation of cyclic nucleotides renders platelets less susceptible to activation signals, further modulating blood rheology through reduced cellular interactions.

Disgren (Triflusal) is a prescription medicine approved solely for oral administration, typically provided in a 300 mg hard capsule form. The official daily dosing schedule for adults is set at either 600 mg or 900 mg. The 600 mg daily dose may be taken as a single dose or divided into two doses, while the 900 mg regimen is typically administered in three divided doses, establishing a clear frequency pattern for long-term use in secondary management protocols.

For administration, the capsule must be swallowed with a sufficient amount of fluid, and regulatory instructions recommend that the intake be preferably with meals. Regarding specific populations, the dosing regimen for older adults mirrors the standard adult doses. However, the medicine's use is not established for children under 18 years of age. Special care is required upon initiating treatment for patients with liver or kidney impairment due to limitations in clinical experience.

A critical, mandatory procedural instruction requires that the administration of Triflusal be suspended seven days prior to any scheduled surgical procedure, defining a necessary protocol for pre-operative management. The entirety of these official instructions strictly governs the intake quantity, timing, and conditions of use, serving as the regulatory blueprint for its proper administration.

Research Evidence / Overview of Studies for Disgren

Evidence for Use in Secondary Prevention of Stroke and TIA

The research for Disgren in the secondary prevention setting, which includes people who have already experienced an ischemic stroke or a transient ischemic attack (TIA), utilized large, randomized, double-blind clinical trials.

Researchers monitored groups of adult patients over long time intervals, some lasting for a mean follow-up of over two-and-a-half years. The primary outcomes research monitored the rates of a composite endpoint of serious vascular events, which included recurrent nonfatal stroke, nonfatal myocardial infarction, or death due to vascular causes.

When large-scale trials and subsequent meta-analyses compared the agents, the data showed patterns related to no significant difference in the frequency of these serious vascular events when measured against Aspirin. However, the studies reported measurements that indicated a pattern of a lower frequency of hemorrhagic complications (both major and minor bleeding episodes, including central nervous system bleeding) observed in the group taking Disgren, when compared with the group taking Aspirin.

---

Evidence for Use Following Acute Heart Events

Research has also explored the use of Disgren in patients shortly after they have experienced an acute myocardial infarction (heart attack). These studies were randomized and monitored patients over a shorter, acute time frame of 35 days.

The primary research question for this acute-phase study was whether Disgren performed similarly to Aspirin in preventing a combined endpoint of death, non-fatal reinfarction, or a non-fatal cerebrovascular event. The research described measured patterns indicating that the observation of non-fatal cerebrovascular events was associated with a lower measured frequency in the Disgren-treated group during this short observation period. Overall, the studies reported measurements that indicated no significant difference was found between the comparison groups for the primary combined outcome.

---

What the Research Indicates is Still Uncertain

Despite the existence of large randomized trials, some areas of research remain uncertain. For instance, meta-analyses reported that while the findings show no statistical difference in the measured composite outcomes between Disgren and Aspirin, the analysis cannot exclude moderate differences in measured endpoints that may be related to differences in patient-specific response. Furthermore, comparative evidence is lacking from large-scale, long-term randomized trials when comparing Disgren directly against other commonly used antiplatelet agents, such as clopidogrel.

Common questions about Disgren (FAQ)

Q: How quickly should I expect Disgren to start working after I begin taking it?

Studies on the drug’s pharmacokinetics indicate that the main active substance of Disgren reaches its maximum concentrations in the blood after approximately 4 to 5 hours. This data relates to when the active substance is most concentrated in the body. The medication is primarily prescribed for long-term prevention of vascular events.

---

Q: Is it normal to feel a slight headache when first starting Disgren?

Official product information lists headache as a common side effect, meaning it may affect up to 1 in 10 people. These effects are usually considered mild. As with any new medicine, if a headache persists or worsens, consult a healthcare provider.

---

Q: Are there any specific foods or supplements that should be avoided while on Disgren?

Regulatory instructions recommend that the medicine be taken preferably with meals. Aside from interactions with certain other prescribed medicines, official regulatory documents do not specify particular foods or non-herbal vitamins/supplements to restrict while taking Disgren.

---

Q: Does Disgren affect blood pressure readings?

Official information includes high blood pressure as an uncommon side effect. This means the symptom may affect up to 1 in 100 people, suggesting it is not a frequently reported occurrence among users.

---

Q: Can older adults safely take Disgren, or are there special precautions?

Official dosing protocols for older adults are consistent with the standard adult dose. However, caution is required when initiating treatment, and those with existing kidney or liver issues are advised to exercise special care due to limited clinical experience in these specific populations.

---

Q: If I miss a dose of Disgren, what is the generally accepted advice?

If you forget a dose, official guidance states that you should not take a double dose to make up for the missed one. You should simply take the next scheduled dose at its regular time and continue with your usual routine.

---

Q: What happens if I stop taking Disgren suddenly?

The medicine is prescribed to prevent recurrence of cardiovascular events. Official guidance emphasizes that you should not stop taking this medicine without the explicit instruction of a healthcare provider, as this is intended to prevent recurrence of the events it manages.

---

Q: Are there any known long-term effects of taking Disgren for several years?

Disgren is used in long-term secondary prevention protocols, with clinical trials lasting over two and a half years. The primary safety concern associated with all antiplatelet medicines, including Disgren, is the inherent risk of bleeding or hemorrhagic events, which requires ongoing vigilance throughout the treatment period.

---

Q: What is the half-life of Disgren in the body?

The active metabolite of Disgren, the substance responsible for the antiplatelet action, has an elimination half-life of approximately 4 to 5 hours. The half-life refers to the time it takes for half of the substance to be cleared from the bloodstream.

---

Q: Why is Disgren sometimes prescribed after a stent placement?

Official indications for Disgren include use after certain vascular procedures, specifically coronary bypass graft surgery, to reduce the risk of the graft becoming blocked (occlusion). This indication is related to the drug's use in post-operative cardiovascular care.

---

Q: What's the difference between Disgren and aspirin in terms of how they work?

Disgren is chemically related to aspirin but functions with a differentiated mechanism. Like aspirin, it inhibits the COX-1 enzyme to block TXA2 synthesis. However, Disgren also has differentiated mechanisms, including effects on vascular relaxation and anti-adhesion.

---

Q: Does Disgren need to be taken with food, or can it be taken on an empty stomach?

Official administration instructions state that the capsules should be swallowed with fluid and are recommended to be taken preferably with meals. This is the standard guidance for proper intake.

---

Q: What patient groups are generally excluded from using Disgren?

Disgren is strictly contraindicated (not suitable) for individuals who have active bleeding, an active or recurrent stomach ulcer, or a known hypersensitivity (severe allergy) to the drug, its components, or other salicylates.

---

Q: How long does it take for Disgren to completely leave the system after stopping?

Based on the half-life of the active metabolite (approximately 5 hours), the medicine is expected to be substantially eliminated from the body within a day after the last dose.

---

Q: Why does my prescription bottle for Disgren have a warning about bleeding?

The warning is required because Disgren is classified as an antiplatelet agent. Its fundamental mechanism of action is to reduce the blood's ability to clot, which inherently carries a safety risk of increased bleeding or hemorrhage, requiring vigilance from all patients.

---

Q: Are there any studies on Disgren use during pregnancy or breastfeeding?

Official product information states that the safety and effectiveness of Disgren during pregnancy or while breastfeeding are not established. Its use in these circumstances must be determined by a doctor after carefully weighing the potential benefits and risks.

---

Q: Does Disgren cause any changes to vision?

Official safety information lists double vision (diplopia) as an uncommon side effect. This means it has been reported in clinical studies but is not commonly observed.

How to Store and Dispose of Disgren?

The storage and disposal of Disgren (Triflusal) must strictly adhere to the conditions mandated by the official regulatory labeling.

Official Storage Requirements

The medicine must not be stored above 25ºC. To protect the product from environmental factors, it is required to be kept in the original package to shield it from moisture. For safety, the medicine must be kept out of the sight and reach of children.

It is mandatory not to use the capsules after the expiry date (EXP/CAD) printed on the package.

Disposal Instructions

Medications should not be disposed of by flushing them down a toilet or throwing them into household waste. Unused or expired Disgren must be returned to a pharmacy's designated collection point or drug take-back program. Following these pharmaceutical waste protocols helps prevent environmental contamination.